Coronavirus disease
Conditions
Interventions
Group 1: 123I-mIBG Scintigraphy
Sponsors
Universitätsklinikum Augsburg - Nuklearmedizin
Eligibility
Sex/Gender
All
Age
18 Months to No maximum
Inclusion criteria
Inclusion criteria: - Persons tested positive for SARS-CoV-2 infection by RT-PCR, in whom COVID-19 has led to admission or a stay at the university hospital and who already have a negative PCR of a nasopharyngeal swab before study entry. - Patients aged >/= 18 years at the start of the study. - Patients who are willing and able to understand and follow the study protocol and who have dated and signed an informed consent form.
Exclusion criteria
Exclusion criteria: - Patients with known previous cardiac disease and/or previous cardiovascular medication of any kind, such as coronary artery disease without or with subsequent revascularisation by PCI or bypass surgery, heart failure, vitiation, cardiac arrhythmias (e.g. atrial fibrillation), high blood pressure. - Patients with a pacemaker or ICD, or patients undergoing cardioversion. - Patients with suspected or known significant allergic reaction or anaphylaxis to iodine or iodine-containing agents. - Patients with severe non-cardiac disease associated with significant elevation of plasma catecholamines, including pheochromocytoma. - Patients with claustrophobia or other conditions that make it impossible to remain supine for up to one hour. - Patients with renal insufficiency (serum creatinine >2.0 mg/dl or GFR < 30 ml/min). - Patients who have already participated in a study with ionising radiation within the last 12 months. - Patients with type I or II diabetes mellitus, with neurological diseases such as Parkinson's disease, multisystem atrophy or atypical Parkinson's syndromes or other diseases which may affect the autonomic nervous system. - Pregnant or breastfeeding women - Minors and patients with mental illness or patients who are unable to provide written informed consent. - Haemodynamically unstable patients or patients with acute coronary syndrome (ST elevation myocardial infarction, non-ST elevation myocardial infarction, unstable angina). - Patients with sepsis, septic shock or systemic inflammatory response syndrome (SIRS)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To characterise long-term cardiac damage in COVID-19 patients after surviving the acute phase using 123I-MIBG uptake. | — |
Secondary
| Measure | Time frame |
|---|---|
| No Secondary Outcome | — |
Countries
Germany
Contacts
Public ContactAlessandro Liebich
Universitätsklinikum Augsburg
Outcome results
None listed